Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,094 | 0,104 | 01.02. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
06.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
23.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
11.12.24 | Viva Biotech Establishes New Branch in Boston | 2 | Contract Pharma | ||
11.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
11.12.24 | Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion | 244 | PR Newswire | HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in... ► Artikel lesen | |
VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
02.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
14.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
06.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
30.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
15.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
08.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
27.09.24 | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT COMPLETION OF JOINT-STOCK CONVERSION OF VIVA SHANGHAI AND CHANGE OF ROLES OF CO-CHIEF FINANCIAL OFFICER | - | HKEx | ||
26.09.24 | VIVA BIOTECH (01873): INTERIM REPORT 2024 | - | HKEx | ||
25.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
13.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
13.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS (REVISED) | 1 | HKEx | ||
05.09.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
29.08.24 | Viva Biotech Holdings: Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | 88 | PR Newswire | Results Highlights for Interim Results ended 30 June 2024
Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS... ► Artikel lesen | |
29.08.24 | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE | - | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 2,732 | +0,37 % | Valneva: Rallye ins Stocken geraten! | Valneva ISIN: FR0004056851 hat sich von den Tiefstständen aus der Vorwoche erholt, aber es sieht nach einer Fortsetzung der Seitwärtsbewegung aus. Bei einem Schlusskurs oberhalb von 2,41 Euro wäre der... ► Artikel lesen | |
NOVONESIS | 54,60 | -0,26 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
GENMAB | 192,40 | +1,37 % | GENMAB A/S - 6-K, Report of foreign issuer | ||
ARBUTUS BIOPHARMA | 3,158 | -1,80 % | Arbutus Biopharma Aktie: Portfolioerweiterungen im Fokus | Die Arbutus Biopharma Corporation verzeichnete am 18. Januar 2025 eine leichte Abwärtsbewegung an der Börse. Der Aktienkurs des Biotech-Unternehmens sank um 0,62 Prozent auf 3,20 USD. Die Marktkapitalisierung... ► Artikel lesen | |
BEIGENE LTD ADR | 218,00 | +0,93 % | ImmunityBio announces collaboration with Beigene | ||
MOLECULIN BIOTECH | 2,450 | 0,00 % | MBRX-Aktie erreicht 52-Wochen-Tief bei 1,46 US-Dollar | ||
SINO BIOPHARM | 0,374 | +2,75 % | Sino Biopharmaceutical-Aktie legt um 3,98 Prozent zu (0,3655 €) | An der Börse liegt die Sino Biopharmaceutical-Aktie aktuell im Plus. Zuletzt zahlten Investoren für die Aktie 0,37 Euro. Der Anteilsschein von Sino Biopharmaceutical verzeichnet derzeit einen Wertanstieg... ► Artikel lesen | |
VERICEL | 56,50 | 0,00 % | VCEL Stock Touches 52-Week High at $61.5 Amidst Strong Growth | ||
SENSEI BIOTHERAPEUTICS | 0,470 | +3,07 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
BIOXCEL THERAPEUTICS | 0,326 | +4,56 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
MUSTGROW BIOLOGICS | 0,888 | +1,37 % | Mustgrow Biologics Corp: Mustgrow Biologics acquisition of NexusBioAg assets | ||
ZAI LAB LTD ADR | 27,400 | +3,79 % | Zai Lab Gets FDA Orphan Drug Designation For ZL-1310 To Treat Small Cell Lung Cancer | BEIJING (dpa-AFX) - Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a potential highly active first-in-class... ► Artikel lesen | |
REGENXBIO | 7,700 | -1,28 % | AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program | Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are... ► Artikel lesen | |
AKEBIA | 2,216 | +2,78 % | Akebia Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
CSTONE PHARMACEUTICALS | 0,280 | 0,00 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE AND STEINCARES ENTER INTO STRATEGIC PARTNERSHIP TO MARKET SUGEMALIMAB IN LATIN AMERICA |